GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Century Therapeutics Inc (NAS:IPSC) » Definitions » Beneish M-Score

IPSC (Century Therapeutics) Beneish M-Score : 73.02 (As of Jun. 18, 2025)


View and export this data going back to 2021. Start your Free Trial

What is Century Therapeutics Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Warning Sign:

Beneish M-Score 73.02 higher than -1.78, which implies that the company might have manipulated its financial results.

The historical rank and industry rank for Century Therapeutics's Beneish M-Score or its related term are showing as below:

IPSC' s Beneish M-Score Range Over the Past 10 Years
Min: -5.1   Med: 0.95   Max: 73.02
Current: 73.02

During the past 6 years, the highest Beneish M-Score of Century Therapeutics was 73.02. The lowest was -5.10. And the median was 0.95.


Century Therapeutics Beneish M-Score Historical Data

The historical data trend for Century Therapeutics's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Century Therapeutics Beneish M-Score Chart

Century Therapeutics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Beneish M-Score
Get a 7-Day Free Trial - - - 2.00 -2.20

Century Therapeutics Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -5.10 -4.48 -3.52 -2.20 73.02

Competitive Comparison of Century Therapeutics's Beneish M-Score

For the Biotechnology subindustry, Century Therapeutics's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Century Therapeutics's Beneish M-Score Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Century Therapeutics's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Century Therapeutics's Beneish M-Score falls into.


;
;

Century Therapeutics Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Century Therapeutics for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 1+0.528 * 1+0.404 * 1.0647+0.892 * 83.8679+0.115 * 0.9986
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 0.0113+4.679 * 0.306027-0.327 * 1.1405
=73.02

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar25) TTM:Last Year (Mar24) TTM:
Total Receivables was $0.0 Mil.
Revenue was 109.164 + 4.173 + 0.791 + 0.771 = $114.9 Mil.
Gross Profit was 109.164 + 4.173 + 0.791 + 0.771 = $114.9 Mil.
Total Current Assets was $169.6 Mil.
Total Assets was $315.6 Mil.
Property, Plant and Equipment(Net PPE) was $87.8 Mil.
Depreciation, Depletion and Amortization(DDA) was $13.3 Mil.
Selling, General, & Admin. Expense(SGA) was $32.8 Mil.
Total Current Liabilities was $14.5 Mil.
Long-Term Debt & Capital Lease Obligation was $47.8 Mil.
Net Income was 76.56 + -36.073 + -31.226 + -31.207 = $-21.9 Mil.
Non Operating Income was -0.038 + -4.221 + 0.25 + -0.012 = $-4.0 Mil.
Cash Flow from Operations was -34.623 + -24.223 + -28.332 + -27.332 = $-114.5 Mil.
Total Receivables was $0.0 Mil.
Revenue was 0.855 + 0.268 + 0.148 + 0.099 = $1.4 Mil.
Gross Profit was 0.855 + 0.268 + 0.148 + 0.099 = $1.4 Mil.
Total Current Assets was $199.8 Mil.
Total Assets was $348.5 Mil.
Property, Plant and Equipment(Net PPE) was $88.3 Mil.
Depreciation, Depletion and Amortization(DDA) was $13.4 Mil.
Selling, General, & Admin. Expense(SGA) was $34.5 Mil.
Total Current Liabilities was $16.1 Mil.
Long-Term Debt & Capital Lease Obligation was $44.3 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(0 / 114.899) / (0 / 1.37)
=0 / 0
=1

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(1.37 / 1.37) / (114.899 / 114.899)
=1 / 1
=1

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (169.631 + 87.764) / 315.609) / (1 - (199.813 + 88.319) / 348.507)
=0.18445 / 0.173239
=1.0647

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=114.899 / 1.37
=83.8679

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(13.362 / (13.362 + 88.319)) / (13.299 / (13.299 + 87.764))
=0.131411 / 0.131591
=0.9986

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(32.821 / 114.899) / (34.547 / 1.37)
=0.285651 / 25.216788
=0.0113

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((47.793 + 14.503) / 315.609) / ((44.251 + 16.065) / 348.507)
=0.197383 / 0.17307
=1.1405

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-21.946 - -4.021 - -114.51) / 315.609
=0.306027

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Century Therapeutics has a M-score of 73.02 signals that the company is likely to be a manipulator.


Century Therapeutics Beneish M-Score Related Terms

Thank you for viewing the detailed overview of Century Therapeutics's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Century Therapeutics Business Description

Traded in Other Exchanges
N/A
Address
25 N 38th Street, 11th Floor, Philadelphia, PA, USA, 19104
Century Therapeutics Inc is a biotechnology company that specializes in leveraging adult stem cells to develop cell therapy products aimed at treating cancer, autoimmune disorders, and inflammatory diseases. Their features a genetically engineered allogeneic cell therapy platform that incorporates induced pluripotent stem cells (iPSCs), CRISPR-mediated precision gene editing, proprietary chimeric antigen receptors (CARs), Allo-EvasionTM technology, and manufacturing capabilities. This comprehensive platform seeks to address the limitations of first-generation cell therapies by optimizing cell product performance, preventing rejection by the host immune system, and reducing development and supply risks.
Executives
Adrienne Farid officer: Chief Operations Officer C/O CENTURY THERAPEUTICS, INC., 3675 MARKET STREET, PHILADELPHIA PA 19104
Douglas Carr officer: VP of Finance and Operations C/O CENTURY THERAPEUTICS, INC., 3675 MARKET STREET, PHILADELPHIA PA 19104
Gregory Russotti officer: Chief Technology Officer C/O CENTURY THERAPEUTICS, INC., 3675 MARKET STREET, PHILADELPHIA PA 19104
Daphne Quimi director C/O AMICUS THERAPEUTICS, INC., 1 CEDAR BROOK DRIVE, CRANBURY NJ 08512
Luis Borges officer: Chief Scientific Officer TWO CORPORATE DRIVE, C/O FIVE PRIME THERAPEUTICS, INC., SOUTH SAN FRANCISCO CA 94080
Timothy P Walbert director 1033 SKOKIE BOULEVARD, SUITE 355, NORTHBROOK IL 60062
Versant Venture Capital Vi, L.p. 10 percent owner ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Joseph Jimenez director ADITUM BIO, 1111 BROADWAY, STE. 1300, OAKLAND CA 94607
Eli Casdin director 1350 AVENUE OF THE AMERICAS, SUITE 1140, NEW YORK NY 10019
Cynthia M Butitta director 3165 PORTER DRIVE, PALO ALTO CA 94304
Kimberly Blackwell director C/O ZENTALIS PHARMACEUTICALS, LLC, 530 SEVENTH AVENUE, SUITE 2201, NEW YORK NY 10018
Rizzuto Carlo director ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Alessandro Riva director C/O CENTURY THERAPEUTICS, INC., 3675 MARKET STREET, PHILADELPHIA PA 19104
Hyam Levitsky officer: President of R&D C/O ANTIGENICS INC., 162 FIFTH AVE., SUITE 900, NEW YORK NY 10010
Osvaldo Flores officer: Chief Executive Officer C/O CENTURY THERAPEUTICS, INC., 3675 MARKET STREET, PHILADELPHIA PA 19104